Xwpharma Ltd.

Xenoport, Inc.

Daniel M Canafax

William W Xiang

Sami Karaborni

Jia-Ning Xiang

Jia-ning Xiang

Annette Grave

James Tien

Norbert Pollinger

Stefanie Thiel

Leonard Blum

Nicolas D Kirkland

Ronald W Barrett

Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Modified release compositions of a gamma-hydroxybutyric acid derivative

Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.

Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Controlled release granulations of water-soluble active pharmaceutical ingredients

Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.

Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

Modified release compositions of a GAMMA-hydroxybutyric acid derivative

Pharmaceutical compositions of 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyric acid following oral administration of the pharmaceutical compositions to healthy subjects are disclosed.

Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative

Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and &#x3b3;-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.

Pharmacokinetics of combined release formulations of a &#x3b3;-hydroxybutyric acid derivative

Granulations with granules having a high loading of an active pharmaceutical ingredient are disclosed. The active pharmaceutical ingredient has a high aqueous water solubility. The granules have a narrow particle size distribution and a smooth exterior surface.

Pharmaceutical granulations of water-soluble active pharmaceutical ingredients

Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.

Growing community of inventors

Half Moon Bay, CA, United States of America

Daniel M Canafax